Certara Acquires Applied BioMath

Certara Acquires Chemaxon to Expand Drug Discovery Software Capabilities

July 9, 2024

Software

Certara, Inc. has signed a definitive agreement to acquire Chemaxon, a leading cheminformatics software provider, with the transaction expected to close in the second half of 2024, subject to regulatory approvals. The acquisition adds Chemaxon’s discovery-focused cheminformatics tools to Certara’s biosimulation portfolio, enabling a more comprehensive data and predictive-analytics platform spanning discovery through development.

Certara Acquires Vyasa Analytics

January 4, 2023

AI & Machine Learning

Certara, Inc. (Nasdaq: CERT) has acquired Vyasa Analytics, LLC to integrate Vyasa’s deep-learning platform LAYAR and AI capabilities into Certara’s biosimulation software suite. The acquisition expands Certara’s data fabric and AI-driven prediction capabilities to accelerate drug discovery and development.

Certara Acquires Pinnacle 21

October 4, 2021

Software

Certara, Inc. completed the acquisition of Pinnacle 21, a provider of SaaS solutions for clinical data standardization, validation and regulatory-submission readiness. Equity holders of Pinnacle 21 received approximately $250 million in cash and 2,239,717 restricted shares of Certara common stock; Certara said the deal expands its data-sciences and software capabilities and is expected to be accretive to revenue and adjusted EBITDA.

Arsenal Capital Partners Invests $449M in Certara

December 8, 2022

Biotechnology

Arsenal Capital Partners closed a previously announced $449 million stock purchase in Certara, acquiring shares from funds controlled by EQT Private Equity and becoming a long-term minority investor. As part of the transaction Arsenal appointed Operating Partner David Spaight to Certara's board while Stephen McLean remains a director; Arsenal agreed to a two-year lock-up on the newly purchased shares.

Optibrium Acquires BioPharmics LLC

August 31, 2023

Software

Optibrium, a Cambridge-based developer of software and AI solutions for small-molecule drug discovery, has acquired BioPharmics LLC to expand its 3D ligand- and structure-based drug design and visualisation capabilities. The acquisition brings BioPharmics' algorithms and products (including ForceGen, Surflex-Dock, eSim and QuanSA) and its founding scientists into Optibrium's StarDrop platform to strengthen 3D modelling, docking and binding-affinity prediction functionality.

CertiPath and ZEVA Acquire SAFE-BioPharma

May 31, 2019

Cybersecurity

CertiPath and ZEVA jointly acquired SAFE-BioPharma, a provider of high-assurance digital identity and cryptography standards for the pharmaceutical, biotechnology, and healthcare industries. The buyers intend to refresh and expand SAFE-BioPharma's policies, specifications, and services to strengthen digital identity trust across regulated health and life-science organizations.